Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy.

Kim EK, Kim JH, Kim HA, Seol H, Seong MK, Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC, Noh WC.

Anticancer Res. 2013 Sep;33(9):4073-9.

PMID:
24023352
2.

Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.

Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC.

Breast Cancer Res Treat. 2011 Feb;126(1):93-9. doi: 10.1007/s10549-010-1315-z. Epub 2010 Dec 24.

PMID:
21184268
3.

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS.

Breast Cancer Res Treat. 2008 Aug;110(3):477-83. Epub 2007 Sep 6.

PMID:
17805960
4.

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

Beelen K, Hoefnagel LD, Opdam M, Wesseling J, Sanders J, Vincent AD, van Diest PJ, Linn SC.

Int J Cancer. 2014 Sep 1;135(5):1257-63. doi: 10.1002/ijc.28769. Epub 2014 Feb 27.

5.

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 21;16(1):R6. doi: 10.1186/bcr3598.

6.

Determinants of rapamycin sensitivity in breast cancer cells.

Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F.

Clin Cancer Res. 2004 Feb 1;10(3):1013-23.

7.

Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.

Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y.

Clin Breast Cancer. 2015 Jun;15(3):197-203. doi: 10.1016/j.clbc.2014.12.002. Epub 2014 Dec 24.

PMID:
25600244
8.
9.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

10.

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.

Breast Cancer Res Treat. 2011 Aug;128(3):725-34. doi: 10.1007/s10549-010-0967-z. Epub 2010 Oct 13.

PMID:
20941539
11.

Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.

Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, Dugu L, Tu Y, Moroi Y, Furue M.

Br J Dermatol. 2009 Aug;161(2):357-63. doi: 10.1111/j.1365-2133.2009.09179.x. Epub 2009 Apr 29.

PMID:
19438435
13.

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Breast Cancer Res Treat. 2013 Jan;137(2):397-406. doi: 10.1007/s10549-012-2376-y. Epub 2012 Dec 15.

14.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
15.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
16.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

17.

PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.

Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S.

J BUON. 2013 Jan-Mar;18(1):44-50.

PMID:
23613387
18.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

19.

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.

Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.

Clin Cancer Res. 2008 May 1;14(9):2673-80. doi: 10.1158/1078-0432.CCR-07-1046.

20.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.

Items per page

Supplemental Content

Write to the Help Desk